Neurodegenerative Disorders

Neurodegenerative Disorders

Neurodegenerative Disorders

On this page

Overview & Classification - Brains Fading Fast

  • Definition: Insidious onset, progressive loss of specific neuronal populations, leading to characteristic clinical syndromes.
  • Core Mechanisms:
    • Proteinopathies: Misfolding & aggregation of proteins (Aβ, Tau, α-synuclein, TDP-43).
    • Shared pathways: Oxidative stress, mitochondrial dysfunction, neuroinflammation, excitotoxicity.
  • Classification (Protein-based):
    • Tauopathies: Alzheimer's (AD), Pick's disease, Progressive Supranuclear Palsy (PSP).
    • α-Synucleinopathies: Parkinson's Disease (PD), Lewy Body Dementia (LBD), Multiple System Atrophy (MSA).
    • Amyloidopathies: AD (Aβ component).
    • TDP-43 Proteinopathies: Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Lobar Degeneration (FTLD-TDP). Brain regions affected by neurodegenerative disorders

⭐ Huntington's disease is an autosomal dominant trinucleotide repeat disorder, distinct from most common proteinopathies but also a key neurodegenerative condition.

Alzheimer's Disease - Memory's Thief

  • Pathology: Extracellular amyloid-β (Aβ) plaques & intracellular Tau neurofibrillary tangles (NFTs).
  • Genetics:
    • Early-onset: APP (Chr 21), PSEN1 (Chr 14), PSEN2 (Chr 1).
    • Late-onset risk: APOE ε4 allele.
  • Clinical: 📌 4 A's: Amnesia (anterograde first), Aphasia, Apraxia, Agnosia. Executive dysfunction.
  • Diagnosis:
    • Clinical criteria (e.g., NINCDS-ADRDA).
    • CSF: ↓Aβ42, ↑Total Tau, ↑Phosphorylated Tau.
    • Imaging: Medial temporal lobe (hippocampal) atrophy. PET for amyloid/tau.
    • MMSE score <24/30 indicates cognitive impairment.
  • Management:
    • Cholinesterase inhibitors: Donepezil, Rivastigmine, Galantamine (mild-moderate).
    • NMDA receptor antagonist: Memantine (moderate-severe). Brain MRI: Alzheimer's disease atrophy patterns

⭐ APOE ε4 is the most significant genetic risk factor for late-onset Alzheimer's disease.

Parkinson's Disease - Shakes & Slows

  • Progressive loss of dopaminergic neurons (substantia nigra pars compacta) → ↓ striatal dopamine.
  • Pathology: Lewy bodies (α-synuclein).
  • Motor Symptoms (📌 TRAP):
    • Tremor: Resting, pill-rolling (4-6 Hz), unilateral onset.
    • Rigidity: Cogwheel or lead-pipe.
    • Akinesia/Bradykinesia: Slow movement, micrographia, masked facies.
    • Postural instability: Shuffling gait, festination (late).
  • Non-motor: Anosmia, constipation, REM sleep behavior disorder, depression.
  • Staging: Hoehn & Yahr (Stage 1-5).
  • Rx: Levodopa/Carbidopa, Dopamine agonists, MAO-B inhibitors. Deep Brain Stimulation (DBS) for advanced. Parkinson's Disease Progression in Substantia Nigra

⭐ Asymmetric onset of motor symptoms is a key feature distinguishing PD from other parkinsonian syndromes.

LBD, FTD, HD, Prions - Diverse Decline

FeatureLewy Body Dementia (LBD)Frontotemporal Dementia (FTD)Huntington's Disease (HD)
ClinicalParkinsonism, Visual Hallucinations, Fluctuating Cognition/Alertness. Poor L-DOPA response.Behavioral changes (bvFTD: disinhibition, apathy) or Language (PPA).Chorea, Cognitive (subcortical), Psychiatric (depression). Autosomal Dominant.
Pathologyα-synuclein (cortical Lewy bodies)Tau (Pick bodies) or TDP-43CAG repeats (>39) HTT; Caudate atrophy; ↓GABA, ↓ACh
Onset>60 yrs; RBD common precursor.45-65 yrs; insidious.30-50 yrs.

⭐ LBD: Core feature is visual hallucinations; REM Sleep Behavior Disorder (RBD) is a strong early indicator.

Motor Neuron Disease - Muscles Wasting

  • Progressive neurodegenerative disorder affecting upper motor neurons (UMN), lower motor neurons (LMN), or both, leading to muscle weakness and wasting.
  • UMN Signs:
    • Spasticity, hyperreflexia, ↑muscle tone.
    • Babinski sign positive.
    • Weakness pattern: Pyramidal.
  • LMN Signs:
    • Flaccidity, hyporeflexia/areflexia, ↓muscle tone.
    • Muscle atrophy (wasting), fasciculations.
    • Weakness pattern: Segmental/focal.
  • Bulbar involvement (dysphagia, dysarthria) common. UMN vs LMN signs in Motor Neuron Disease

⭐ Amyotrophic Lateral Sclerosis (ALS) is the most common form, characterized by combined UMN and LMN signs. No sensory or cognitive (usually) impairment initially. Riluzole may offer modest survival benefit (2-3 months).

High‑Yield Points - ⚡ Biggest Takeaways

  • Alzheimer's Disease: Amyloid plaques, tau tangles; ApoE4 risk; most common dementia.
  • Parkinson's Disease: Dopamine loss (substantia nigra); Lewy bodies (α-synuclein); tremor, rigidity, bradykinesia.
  • Huntington's Disease: Autosomal Dominant, CAG repeats (Chr 4); chorea, dementia.
  • ALS: Combined UMN & LMN signs; progressive weakness; SOD1 mutations (familial).
  • Frontotemporal Dementia (FTD): Early behavioral/language changes; Pick bodies (tau) or TDP-43.
  • Lewy Body Dementia (LBD): Fluctuating cognition, visual hallucinations, parkinsonism; REM sleep disorder.
  • Creutzfeldt-Jakob Disease (CJD): Rapidly progressive dementia, myoclonus; prions; spongiform changes.

Practice Questions: Neurodegenerative Disorders

Test your understanding with these related questions

Which of the following is typically not associated with upper motor neuron (UMN) lesions?

1 of 5

Flashcards: Neurodegenerative Disorders

1/10

_____ (dementia or delirium) is associated with a normal pattern on EEG

TAP TO REVEAL ANSWER

_____ (dementia or delirium) is associated with a normal pattern on EEG

Dementia

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial